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Background. Remifentanil is known to cause bradycardia and hypotension. We aimed to
characterize the haemodynamic profile of remifentanil during sevoflurane anaesthesia in children
with or without atropine.
Methods. Forty children who required elective surgery received inhalational induction of anaes-
thesia using 8% sevoflurane. They were allocated randomly to receive either atropine, 20 mg kg1
(atropine group) or Ringer’s lactate (control group) after 10 min of steady-state 1 MAC sevo-
flurane anaesthesia (baseline). Three minutes later (T0), all children received remifentanil
1 mg kg1 injected over a 60 s period, followed by an infusion of 0.25 mg kg1 min1 for 10 min
then 0.5 mg kg1 min1 for 10 min. Haemodynamic variables and echocardiographic data were
determined at baseline, T0, T5, T10, T15 and T20 min.
Results. Remifentanil caused a significant decrease in heart rate compared with the T0 value,
which was greater at T20 than T10 in the two groups: however, the values at T10 and T20 were
not significantly different from baseline in the atropine group. In comparison with T0, there was a
significant fall in blood pressure in the two groups. Remifentanil caused a significant decrease in
the cardiac index with or without atropine. Remifentanil did not cause variation in stroke volume
(SV). In both groups, a significant increase in systemic vascular resistance occurred after admin-
istration of remifentanil. Contractility decreased significantly in the two groups, but this decrease
remained moderate (between 2 and +2 SD).
Conclusion. Remifentanil produced a fall in blood pressure and cardiac index, mainly as a result
of a fall in heart rate. Although atropine was able to reduce the fall in heart rate, it did not
completely prevent the reduction in cardiac index.
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Keywords: anaesthesia, paediatric; anaesthetics i.v., remifentanil; heart, myocardial contractility;
heart, myocardial function; measurement techniques, echocardiography
Accepted for publication: August 12, 2004
Remifentanil hydrochloride is a short-acting opioid of the
phenylpiperidine class which is widely used in adult general
anaesthesia1 and has been used in paediatric anaesthesia.2 3 A
preliminary pharmacokinetic study in children aged 0–18 yr
suggested a pharmacokinetic profile similar to that of adults:
a small volume of distribution, a rapid distribution phase, a
half-life with mean of 3.4–5.7 min and extremely rapid
elimination.3
Remifentanil is known to cause bradycardia and hypo-
tension3–5 but the mechanisms are unclear. The potential for
inducing these side-effects has been one of the reasons
for the relatively infrequent use of remifentanil in children.
The aim of this study was to characterize the haemo-
dynamic profile of remifentanil using non-invasive echocar-
diographic data6 7 during sevoflurane anaesthesia in children
with and without atropine.
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Materials and methods
Forty children aged 0.8–13 yr, classified as ASA physical
status I or II and who required elective surgery, were studied
prospectively after approval of the protocol by our Institu-
tional Human Studies Committee. Informed written parental
consent was obtained. Patients with cardiac and neurological
disease were excluded. The children were not allowed to eat
or drink for 6 h before the operation and were premedicated
30 min before induction of anaesthesia with rectal midazo-
lam 0.3 mg kg1.
Anaesthesia was induced by inhalation of sevoflurane 8%
in oxygen 100% through an open circuit in all patients. After
placement of an i.v. line, the trachea was intubated and the
lungs were ventilated to maintain normocapnia. Sevoflurane
was then reduced to 1 MAC corrected for age for at least
10 min to achieve steady state. At this point (baseline),
children were assigned randomly to receive i.v. (in 4 ml)
either atropine 20 mg kg1 (atropine group) or Ringer’s
lactate (control group). Three minutes later (T0), all children
received a bolus of remifentanil 1 mg kg1 injected over a
60 s period followed by an infusion of remifentanil 0.25 mg
kg1 min1 for 10 min then 0.5 mg kg1 min1 for 10 min.
At the end of the 20 min the study was finished and
surgery could start. No neuromuscular blocking agents
were administered.
During the study the heart rate, peripheral oxygen satura-
tion (Spo2 ) and end-tidal carbon dioxide (PE
0
co2
) were mon-
itored continuously. Non-invasive blood pressure (mm Hg)
was measured every minute using an automated blood pres-
sure cuff with an appropriate cuff size in relation to the size
of the child’s arm. Bradycardia was defined as greater than
20% decrease in heart rate. The following haemodynamic
variables were recorded at baseline, T0, T5, T10, T15 and
T20 min: heart rate, mean blood pressure (MBP), continuous
Doppler, and 2D transthoracic echocardiographic data
(Sonos 1000; Hewlett-Packard, Andover, MA, SA). The
echocardiographic data obtained in each patient included
aortic diameter and shortening fraction (SF). In the long-
axis view of the left ventricular outflow tract (using the 2D
mode), the end-systolic internal aortic diameter (Dao) was
measured, at the annulus, and the aortic sectional area
(SaAo) was calculated as (SaAo=p(Dao)2/4). The SF was
measured by M mode from the parasternal long-axis view of
the left ventricle at the junction of mitral valve leaflets and
the papillary muscle. The left ventricular end-diastolic dia-
meter (LVDD) was measured at the point of maximum
diameter, and the left ventricular end-systolic diameter
(LVSD) was measured at the point of peak upward deflec-
tion of the posterior wall. The posterior wall thickness
(Pwes) was measured at end-systole. The SF was calculated
as (LVDD–LVSD)/LVDD and expressed as a percentage.
The rate-corrected velocity of circumferential fibre short-
ening (VCFc) was calculated using the formula VCFc=
SF/rate-corrected ejection time. The rate-corrected ejection
time was ejection time divided by the square root of the R–R
interval (to correct to a heart rate of 60 beats min1). The left
ventricular end-systolic wall stress (ESWS) was calculated
using the formula: ESWS=(1.35·MBP·LVSD)/[(1+Pwes/
LVSD)·(Pwes)·4].8
Continuous Doppler readings were used to measure the
flow in the ascending aorta from the suprasternal view of the
heart. The audio signal intensity was used to confirm posi-
tioning for maximal aortic blood flow velocities. Because
the angle between the estimated direction of blood flow and
the Doppler beam was <15 or less, no angle correction
of the Doppler signal was made. The mean aortic flow velo-
city (Vao) was calculated using the software of the ultra-
sound system as average velocity multiplied by flow period.
The average of three consecutive flow velocity integrals was
taken. The cardiac index (CI) was calculated from the
volumetric equation: CI (ml kg1 min1)=Vao (cm/s)·
SaAo (cm2)·60/body weight (kg). The systemic vascular
resistance (SVR) was evaluated as the quotient of the
mean blood pressure and CI without measurement of
right atrial pressure.
The VCFc–ESWS relation or SF–ESWS relation can be
used to determine contractility independently of loading
conditions. However, SF, VCFc and ESWS were age- and
body surface area-dependent. As described by Colan and
colleagues, the Z score rather than the absolute value was
used to normalize these calculations, with age- and growth-
related means taken from values established for healthy
children or infants.9 The stress–velocity index for each
child was determined relative to the distribution of this
index in children at the steady state with sevoflurane without
remifentanil and calculated as a normal deviate (Z score).
The stress velocity index was calculated as (X1–M)/SD,
where X1 is the measured VCFc, M is mean VCFc calcu-
lated for the measured ESWS, and SD is the standard devia-
tion of the regression group stress–velocity index. The
stress–shortening index (SSI) was correspondingly quanti-
fied as the normal deviate of fractional shortening for the
given ESWS, obtained in a manner analogous to that
described for the stress–velocity index. The normal value
of the Z score was between 2 and +2.
All echo measurements were obtained by the same obser-
ver, who was not aware of the study hypothesis or the
design details.
Statistical analysis was done using non-parametric tests.
The analysis of the overall evolution of the variables
between the two groups was carried out with Friedman’s
test. Comparisons between groups were made with the
Mann–Whitney test and comparisons within groups with
the Wilcoxon matched test. A probability value less than
0.05 was considered significant. Values are expressed as
median (range).
Results
The clinical characteristics of the children are shown in
Table 1. The groups were similar with regard to age, weight,
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sex, heart rate, mean blood pressure and echographic
haemodynamic data at baseline (Table 1, Figs 1–3).
In comparison with baseline, remifentanil caused a sig-
nificant decrease in heart rate in the control group at T10 and
T20 (Fig. 1). In comparison with baseline, in the atropine
group remifentanil did not cause a decrease in heart rate at
T10 and T20, and heart rate returned to the baseline value at
T20. In comparison with T0 (after pretreatment), remifen-
tanil caused a significant decrease in heart rate in all patients
with or without atropine. These decreases were greater at
T20 than T10 (Fig. 1). There were significantly more chil-
dren in the control group than in the atropine group who
experienced a fall of 20% in the heart rate at T10 (45 vs 0%
respectively) and T20 (75 vs 5%). Administration of remi-
fentanil was associated with a significant reduction in MBP
compared with baseline and after pretreatment (T0) in the
two groups at T10 and T20 (Table 2).
The CI decreased significantly in the two groups after
administration of remifentanil, but this decrease was less
in the atropine group than in the control group (Fig. 2).
The reduction in CI was greater at T20 than T10 in both
groups. There were significantly more children in the control
group than in the atropine group who experienced a fall
of 20% in CI at T10 (50 vs 10% respectively) and T20
(70 vs 25%). In the atropine group, the stroke volume
(SV) decreased soon after the atropine was injected and
before the start of the remifentanil infusion (Table 2).
This fall in SV persisted throughout the study period.
There was no significant variation in SV in both groups
at all times compared with T0. The SVR increased signifi-
cantly compared with baseline and T0 after infusion of
remifentanil in the control group, but an increase was appar-
ent in the atropine group only at T20 (Table 2).
Administration of atropine did not change the stress–
velocity index or the SSI. However, after administration
of remifentanil the stress–velocity index and the SSI
decreased significantly in both groups compared with base-
line and T0, with no significant difference between the
two groups: this decrease remained, however, between 2
and +2 SD of the baseline values (Fig. 3).
Discussion
The decrease in blood pressure induced by remifentanil in
children during sevoflurane anaesthesia was mainly depen-
dent on a fall in CI. Although atropine prevented a fall in
heart rate compared with baseline, this reduced, but did not
prevent, the fall in CI and had minimal effect on the fall in
mean blood pressure.
Table 1 Children’s clinical characteristics in groups receiving either Ringer
lactate (control) or atropine (AT) just before infusion of remifentanil. MBP=
mean blood pressure; E0SEVO=end-tidal sevoflurane concentration
Age (months)
Median
(range)
Weight (kg)
Median
(range)
Sex MBP (mm Hg)
Median
(range)
E0SEVO (%)
Median
(range)
Atropine 50
(8–162)
16.5
(7.7–49)
M=14
F=6
60.5
(50–75)
2.6
(2.3–2.9)
Control 51
(11–134)
17
(8.3–33)
M=14
F=6
61
(53–80)
2.5
(2.3–2.8)
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Fig 1 Heart rate (beats min1) values under remifentanil compared with 1 MAC sevoflurane steady-state values (baseline). T0=time after injection of
atropine (AT) or Ringer (RL); time (min) 5 and 10 under remifentanil at 0.25 mg kg1 min1; time 15 and 20 under remifentanil at 0.5 mg kg1 min1. Vs
baseline, *P<0.05; vs T0, zP<0.05; vs T10, $P<0.05. Open circles correspond to minimum and maximum values.
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Many authors have shown that remifentanil can induce a
decrease in heart rate in adult as well as in paediatric
patients.5 10–17 Indeed, Klemola and colleagues reported a
significant fall of 6–9% in heart rate when remifentanil was
administered at induction of anaesthesia to children who
had been pretreated with atropine before induction.14 The
cardiovascular side-effects of remifentanil appear to be
similar to those of other opioids (such as fentanyl and
*
AT group
RL group
SV
I (Z
-sc
ore
)
T20T15T10T5T0Baseline
Time
–6
–5
–4
–3
–2
–1
0
1
2
3
* * * * * * * $‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡
Fig 3 Contractility values (stress–velocity index, SVI) under remifentanil compared with 1 MAC sevoflurane steady-state values (baseline). T0=time
after injection of atropine (AT) or Ringer (RL); time (min) 5 and 10 under remifentanil at 0.25 mg kg1 min1; time 15 and 20 under remifentanil at
0.5 mg kg1 min1. Vs baseline, *P<0.05; vs T0, zP<0.05; vs T10, $P<0.05. Open circles correspond to minimum and maximum values.
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Fig 2 Cardiac index values under remifentanil compared with 1 MAC sevoflurane steady-state values (baseline). T0=time after injection of atropine (AT) or
Ringer (RL); time (min) 5 and 10 under remifentanil at 0.25 mg kg1 min1; time 15 and 20 under remifentanil at 0.5 mg kg1 min1. Vs baseline, *P<0.05;
vs T0, zP<0.05; vs T10, $P<0.05. Open circles correspond to minimum and maximum values.
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alfentanil), although the degree of bradycardia with remi-
fentanil seems greater than with the other opioids. In our
study, remifentanil caused a progressive decrease in heart
rate during the first level of infusion (0.25 mg kg1 min1)
and then a further reduction during the second level of infu-
sion (0.5 mg kg1 min1), suggesting a dose-dependent
effect of remifentanil on heart rate. In a similar way, Wee
and colleagues found a higher incidence of bradycardia and
hypotension when remifentanil was given to infants with a 1
mg kg1 min1 loading dose compared with an initial infu-
sion of 0.25 mg kg1 min1.10 These results could explain
the high proportion of children with bradycardia in our study
who had not received atropine pretreatment.
Ross and colleagues showed a 17% incidence of remifen-
tanil-related hypotension in a paediatric study in which
atropine was given at the discretion of the anaesthetist.3
Similarly, Klemola and colleagues reported a decrease in
MBP of 11–13% after anaesthetic induction with remifen-
tanil.14 Our results are consistent with these.
In our study, the fall in MBP resulted from a dose-
dependent fall in CI. Although the fall in CI was greater
in the control group, this was offset by a greater increase
in SVR compared with the atropine group, so that the
fall in MBP was similar in the two groups. In the control
group, and in contrast to studies in adults,11 12 remifentanil
had no effect on the stroke volume, while the reduction in
SV in the atropine group was apparent before the admin-
istration of remifentanil. In the control patients, therefore,
the reduction in heart rate can largely explain the reduced
CI caused by remifentanil. Administration of atropine had
no significant effect on CI before remifentanil was given
because the increased heart rate was offset by a fall in SV.
The addition of remifentanil reversed the tachycardia but
had no effect on the SV, thereby reducing the CI. Thus,
irrespective of pretreatment with atropine, remifentanil
reduces the CI below baseline values by causing a reduc-
tion in the absolute (rather than relative to baseline) value
of the heart rate.
We have not been able to find any previous reports of
atropine causing a reduction in SV in children. The reduction
in SV could be due to a loading defect secondary to tachy-
cardia. However, at T20 in the atropine group the SV
remained impaired, whereas the heart rate had returned to
baseline. As atropine did not significantly change the SVR at
T0 in the atropine group, the effect of atropine on SV could
be attributed to a preload decrease, i.e. a vasodilator effect.
This finding could explain the smaller increase in SVR in the
atropine group during the remifentanil infusion.
Myocardial contractility is difficult to quantify in clinical
practice. Using echocardiographic measurements, Colan
and colleagues reported the possibility of determining an
estimate of myocardial contractility in a non-invasive man-
ner and independently of loading conditions in children as
well as in adults.9 This method has already been used suc-
cessfully in paediatric anaesthesia to compare the effects of
different anaesthetics.18–20 In the present study, the myocar-
dial contractility index represented by SSI and the stress–
velocity index appeared to be moderately reduced in the two
groups, remaining between 2 and +2 SD. This allows us
to establish that the effect of remifentanil on myocardial
contractility is probably moderate in healthy children.
No severe adverse effects occurred in our study with
remifentanil. We intentionally used high infusion rates of
remifentanil to allow us to analyse the haemodynamic
effects and safety of remifentanil in children. The same
infusion doses have already been used safely in adults.21
Taking into account the doses of remifentanil used, only
half of the children in the control group experienced a
20% drop of CI, compared with 10% in the atropine
group. All episodes of hypotension (decrease from baseline
>20%) and bradycardia resolved spontaneously without
pharmacological intervention when the rate of remifentanil
infusion was decreased.
Thus, during sevoflurane anaesthesia in children, remi-
fentanil decreased mean blood pressure and CI mainly
because of a decrease in heart rate. Although pretreatment
Table 2 Percentage changes (D) in haemodynamic values in comparison with baseline value at 1 MAC end-tidal sevoflurane steady-state. Vs baseline, *P<0.05; vs
T10, zP<0.05. SV=stroke volume; SVR=systemic vascular resistance; HR=heart rate; MBP=mean blood pressure. T0=after pretreatment, before remifentanil;
T10=0.25 mg kg1 min1; T20=0.5 mg kg1 min1
D (%) groups T0 T10 T20
Median Range Median Range Median Range
D HR
Atropine +20* (2, 43) +7 (16, 32) 0z (23, 31)
Control 0 (1, 2) 0* (32, 8) 26*z (31, 13)
D MBP
Atropine +16 (9, 21) 8* (38, 9) 11* (31, 26)
Control 0 (4, 3) 12* (29, 7) 15*z (38, 2)
D SVR
Atropine +2 (22, 33) 0 (21, 15) +8*z (14, 50)
Control 1 (6, 7) +12* (7, 44) +15*z (14, 52)
D SV
Atropine 13* (28, 1) 11* (30, 3) 18* (29, 0)
Control 0 (3, 5) 4 (24, 19) 3 (27, 18)
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with atropine was able to limit the effect of remifentanil on
heart rate, its potential beneficial effects on blood pressure
and CI appeared to be less. The specific effect of atropine on
SV in children during sevoflurane anaesthesia requires
further investigation.
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